

FINANCIAL RELATIONSHIPS WITH INELIGIBLE COMPANIES

In the interest of maintaining the independence of its CME activities and in accordance with the policies of the Accreditation Council for Continuing Medical Education (ACCME), the IAS–USA requires all persons with control of content (eg, course faculty, Scientific Leadership Board, Governance Board, and program staff) to disclose any financial relationships that have had with ineligible companies (previously defined as “commercial interests”) within the previous 24 months. Any real or apparent conflicts of interest of those parties are resolved prior to the CME activity being delivered and have been mitigated. Individuals who refuse to disclose financial relationships may not participate in an IAS–USA CME activity. The **ACCME defines ineligible companies** as “those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.” Below are the financial interests that faculty members of this course have had within the past 24 months. View the [Faculty Financial Disclosure Policy](#) on the IAS–USA website.

THE IAS–USA ANNUAL UPDATE ON HIV MANAGEMENT IN CHICAGO, ILLINOIS NOVEMBER 18, 2025

Course Presenters and Panelists	
Katharine J. Bar, MD Associate Professor of Medicine University of Pennsylvania Philadelphia, PA	Dr Bar reported serving as a consultant for ViiV Healthcare, Merck & Co, Inc, and AbbVie, Inc. (Updated October 27, 2025)
Judith S. Currier, MD Professor of Medicine University of California Los Angeles Los Angeles, CA	Dr Currier reported serving as a consultant for Merck & Co, Inc. (Updated October 25, 2025)
Rajesh T. Gandhi, MD Professor of Medicine Harvard University Boston, MA	Dr Gandhi reported no relevant financial relationships with ineligible companies. (Updated October 26, 2025)
Roy M. Gulick, MD, MPH Rochelle Belfer Professor in Medicine Weill Cornell Medicine New York, NY	Dr Gulick reported no financial relationship with ineligible companies. (Updated October 25, 2025)
Steven C. Johnson, MD Professor of Medicine University of Colorado School of Medicine Aurora, CO	Dr Johnson reported no relevant financial relationships with ineligible companies. (Updated October 27, 2025)
Jacob Walker, MD Associate Professor University of Colorado Aurora, CO	Dr Walker reported no relevant financial disclosures with ineligible companies. (Updated October 31, 2025)

IAS–USA CME Planners and Reviewers	
Constance A. Benson, MD, FACP Professor of Medicine University of California San Diego San Diego, CA	Dr Benson reported fees for participation in review activities, eg, data monitoring boards, statistical analysis, or end point adjudication committees with ViiV Healthcare and consulting or advisor fee with Antiva Biosciences, Inc. (Updated July 9, 2025)
Aniruddha Hazra, MD Associate Professor of Medicine University of Chicago Chicago, IL	Dr Hazra reported serving as a consultant to Abbott Laboratories, Gilead Sciences, Inc, and ViiV Healthcare. He reported receiving research grant funding from Gilead Sciences, Inc. (Updated October 29, 2025)
Donna M. Jacobsen Executive Director/President IAS–USA San Francisco, CA	Ms Jacobsen reported no relevant financial relationships with ineligible companies. (Updated November 4, 2025)

IAS–USA Boards
The nonstaff members of the IAS–USA Scientific Advisory Board and Governance Board are not compensated for their roles in governing and overseeing the IAS–USA and content development. Please see the About page on the IAS–USA website for information about board members and a link to up-to-date financial disclosure information.